Blood–brain barrier molecular carriers for Parkinson’s disease

ABL Bio’s first-in-class bispecific antibodies for Parkinson’s disease combine unprecedented blood–brain barrier penetration with a robust mechanism of action for improved therapeutic efficacy. The company is looking for partners to codevelop or out-license bispecific antibodies able to penetrate the blood–brain barrier.

Like Comment
Page of
Go to the profile of ABL Bio

ABL Bio

ABL Bio is biotech research company focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases. 1. Lead Molecule (ABL001): Bispecific antibody targeting VEGF and Dll4 (Phase 1, Q4, 2017) 2. ADC (Antibody Drug Conjugate) projects 3. T cell engaging Bispecific antibody 4. Immunooncology MoAb 5. Immunooncology Bispecific antibody 6. Synuclein targeting antibody with BBB-Crossing Trojan Horse Bispecific Antibody

No comments yet.